07:20 AM EDT, 06/26/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Wednesday that it has received approval in China for its cancer medicine Tagrisso in combination with chemotherapy for non-small cell lung cancer.

The approved indication is for adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated NSCLC with tumors of certain mutations.

China's National Medical Products Administration gave the approval based on a late-stage trial that showed the regimen reduced the risk of disease progression or death by nearly half versus standard of care among Chinese patients, the company said.

Price: 79.89, Change: +0.14, Percent Change: +0.18